|
Published by: Global Markets Direct
Published: Aug. 31, 2012 - 445 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- HIV / AIDS Overview
- Therapeutics Development
- An Overview of Pipeline Products for HIV / AIDS
- HIV / AIDS Therapeutics under Development by Companies
- HIV / AIDS Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- HIV / AIDS Therapeutics – Products under Development by Companies
- HIV / AIDS Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in HIV / AIDS Therapeutics Development
- Bristol-Myers Squibb Company
- Johnson & Johnson
- Abbott Laboratories
- Vical Incorporated
- Shionogi & Co., Ltd.
- GlaxoSmithKline plc
- Nektar Therapeutics
- Inovio Biomedical Corporation
- Gilead Sciences, Inc.
- VIRxSYS Corporation
- Merck & Co., Inc.
- United Biomedical, Inc.
- Lentigen Corporation
- Myriad Genetics, Inc.
- Sangamo BioSciences, Inc.
- Cytokine PharmaSciences, Inc.
- Generex Biotechnology Corporation
- Ceragenix Pharmaceuticals, Inc.
- Nanotherapeutics, Inc.
- Ambrilia Biopharma Inc.
- Panacos Pharmaceuticals, Inc.
- Biotron Limited
- Aphios Corporation
- Achillion Pharmaceuticals, Inc.
- Esteve Group
- Japan Tobacco Inc.
- Pfizer Inc.
- SuperGen, Inc.
- Hadasit Medical Research Services & Development Ltd
- Avexa Limited
- Koronis Pharmaceuticals, Inc.
- Alfacell Corporation
- Geron Corporation
- GeoVax Labs, Inc.
- Hemispherx Biopharma, Inc.
- Celldex Therapeutics, Inc.
- iCo Therapeutics Inc.
- Enzo Biochem, Inc.
- Ardea Biosciences, Inc.
- Medivir AB
- Bio-Bridge Science, Inc.
- Mymetics Corporation
- NanoViricides, Inc.
- Nutra Pharma Corporation
- ConjuChem Biotechnologies Inc.
- Critical Outcome Technologies Inc.
- CytoGenix, Inc.
- ADVENTRX Pharmaceuticals
- Starpharma Holdings Limited
- Immuron Limited
- Samaritan Pharmaceuticals, Inc.
- Takara Bio Inc.
- BioAlliance Pharma SA
- Transgene Biotek Ltd
- Paloma Pharmaceuticals, Inc.
- Antigen Express, Inc.
- Functional Genetics, Inc.
- BioClonetics Incorporated
- Nutri Pharma ASA
- Pharmaplaz Ltd.
- BioMAS Ltd.
- Vironova AB
- ViroStatics, srl
- Argos Therapeutics, Inc.
- Cytheris SA
- Altor BioScience Corporation
- PX’Therapeutics SA
- Osel Inc.
- Heat Biologics, Inc.
- AiCuris GmbH & Co. KG
- AlphaVax, Inc.
- Indus Biotech Private Limited
- Locus Pharmaceuticals, Inc.
- Presidio Pharmaceuticals, Inc.
- Theraclone Sciences, Inc.
- Frontier Biotechnologies, Inc.
- Kainos Medicine, Inc.
- Viral Genetics, Inc.
- Concert Pharmaceuticals, Inc.
- Myriad Pharmaceuticals, Inc.
- CytoDyn, Inc.
- GeneCure LLC
- Omeros Corporation
- Oncolys BioPharma Inc.
- Globeimmune, Inc.
- Etubics Corporation
- Immunocore Limited.
- Canopus BioPharma Incorporated
- Discovery Genomics, Inc.
- PepTcell Limited
- Arisyn Therapeutics Inc.
- TVAX Biomedical, LLC
- Tobira Therapeutics, Inc.
- Genetic Immunity, LLC
- TNI Pharmaceuticals, Inc.
- GenPhar, Inc.
- Medisyn Technologies, Inc.
- Napo Pharmaceuticals, Inc.
- Pharis Biotec GmbH
- Immunomic Therapeutics, Inc.
- GeoVax, Inc.
- Heptares Therapeutics Ltd.
- VIRIOM Ltd.
- CONRAD
- ViiV Healthcare
- RFS Pharma, LLC
- Helix Therapeutics LLC
- Vichem Chemie Research Ltd.
- ImQuest Life Sciences
- HIV / AIDS – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Cobicistat - Drug Profile
- 1349572 - Drug Profile
- Crofelemer - Drug Profile
- Crofelemer - Drug Profile
- JTK-303 - Drug Profile
- JTK-303 - Drug Profile
- SP-01A - Drug Profile
- Ampligen - Drug Profile
- Apricitabine - Drug Profile
- Quad - Drug Profile
- Tenofovir + Emtricitabine + Efavirenz - Drug Profile
- Dapivirine Ring - Drug Profile
- Emtricitabine + Tenofovir Disoproxil Fumarate - Drug Profile
- Zidovudine + Lamivudine + Nevirapine - Drug Profile
- Zidovudine + Lamivudine + Efavirenz - Drug Profile
- Aluvia - Drug Profile
- Aluvia + Raltegravir - Drug Profile
- Nevirapine - Drug Profile
- Emtricitabine + Tenofovir Disoproxil Fumarate + Lopinavir + Ritonavir + Nevirapine - Drug Profile
- Proleukin + Anti-HIV Therapy - Drug Profile
- Emtricitabine + Tenofovir Disoproxil Fumarate + Ritonavir + Atazanavir - Drug Profile
- Emtricitabine + Tenofovir Disoproxil Fumarate + Raltegravir - Drug Profile
- Emtricitabine + Tenofovir Disoproxil Fumarate + Darunavir + Ritonavir - Drug Profile
- Erythromycin + Nevirapine + Ampicillin Sodium + Metronidazole - Drug Profile
- Valacyclovir - Drug Profile
- Buprenorphine + Naloxone - Drug Profile
- Prednisone - Drug Profile
- Raltegravir + Truvada - Drug Profile
- Stavudine + Lamivudine + Abacavir - Drug Profile
- Emtricitabine + Tenofovir - Drug Profile
- Tenofovir - Drug Profile
- Stavudine + Lamivudine + Nevirapine - Drug Profile
- Abacavir + Lamivudine + Nevirapine - Drug Profile
- Zidovudine + Lamivudine + Abacavir - Drug Profile
- GPO-VIR S + GPO-VIR Z - Drug Profile
- GPO-VIR Z - Drug Profile
- Truvada + Nevirapine - Drug Profile
- Didanosine + Abacavir + Kaletra - Drug Profile
- Zidovudine + Lamivudine + Kaletra - Drug Profile
- Proleukin + Paracetamol + Ibuprofen + Ondansetron + Codeine Phosphate - Drug Profile
- Proleukin + Paracetamol + Ibuprofen + Metoclopramide + Codeine Phosphate - Drug Profile
- Isentress + Kaletra - Drug Profile
- Stavudine + Lamivudine + Nevirapine - Drug Profile
- Stavudine + Lamivudine + Efavirenz - Drug Profile
- Abacavir + Lamivudine + Nevirapine - Drug Profile
- Abacavir + Lamivudine + Efavirenz - Drug Profile
- Zidovudine + Lamivudine + Nevirapine - Drug Profile
- Zidovudine + Lamivudine + Efavirenz - Drug Profile
- Lopinavir + Ritonavir + Zidovudine - Drug Profile
- Remune - Drug Profile
- Zidovudine + Nevirapine - Drug Profile
- Zidovudine - Drug Profile
- Indinavir + Ritonavir + Abacavir + Didanosine + Proleukin - Drug Profile
- Darunavir + Ritonavir - Drug Profile
- Tenofovir Disoproxil Fumarate - Drug Profile
- Tenofovir + Emtricitabine + Efavirenz - Drug Profile
- Isentress + Celsentri + Prezista + Norvir + Truvada - Drug Profile
- Sustiva + Epzicom - Drug Profile
- Atazanavir + Ritonavir + Abacavir + Lamivudine - Drug Profile
- Lamivudine + Zidovudine + Nelfinavir + Efavirenz - Drug Profile
- Nevirapine + Lopinavir + Ritonavir - Drug Profile
- Ritonavir + Saquinavir + Efavirenz - Drug Profile
- Ziodovudine + Alpha Interferon - Drug Profile
- Kaletra - Drug Profile
- Atazanavir + Emtricitabine + Tenofovir Disoproxil Fumarate + Ritonavir - Drug Profile
- Enfuvirtide + Raltegravir + Darunavir + Tipranavir + Etravirine + Maraviroc - Drug Profile
- Abacavir + Lamivudine + Atazanavir + Ritonavir - Drug Profile
- Abacavir Sulfate + Didanosine + Efavirenz + Lamivudine + Lopinavir + Nevirapine + Zidovudine - Drug Profile
- Lopinavir + Ritonavir + Nucleoside Reverse Transcriptase Inhibitors + PEG-IFNa 2a + Ribavirin - Drug Profile
- Raltegravir + Maraviroc + Tenofovir + Emtricitabine - Drug Profile
- Viread + Aluvia - Drug Profile
- Truvada + Nevirapine - Drug Profile
- Truvada + Zidovudine - Drug Profile
- Truvada - Drug Profile
- Abacavir + Lamivudine + Efavirenz - Drug Profile
- Darunavir + Ritonavir + Raltegravir - Drug Profile
- Atazanavir + Didanosine + Efavirexnz + Emtricitabine + Tenofovir Disoproxil Fumarate + Lamivudine + Lopinavir + Ritonavir + Nevirapine + Stavudine + Zidovudine - Drug Profile
- Raltegravir + Maraviroc + Emtricitabine + Tenofovir + Lopinavir + Ritonavir - Drug Profile
- Lopinavir + Ritonavir - Drug Profile
- Darunavir + Ritonavir - Drug Profile
- Isentress + Celsentri + Truvada + Kaletra - Drug Profile
- Truvada + Raltegravir - Drug Profile
- Fuzeon + Truvada + Kaletra - Drug Profile
- Abacavir - Drug Profile
- Abacavir + Lamivudine + Efavirenz - Drug Profile
- Efavirenz - Drug Profile
- Etravirine - Drug Profile
- Tenofovir - Drug Profile
- Celsentri + Antiretroviral Therapy - Drug Profile
- Lamivudine + Tenofovir + Atazanavir + Ritonavir - Drug Profile
- 572-Trii - Drug Profile
- Reyataz + Cobicistat - Drug Profile
- Cobicistat + Prezista - Drug Profile
- Pentamidine - Drug Profile
- RemuneX - Drug Profile
- Atazanavir + Lamivudine + Ritonavir - Drug Profile
- HIV / AIDS Therapeutics – Drug Profile Updates
- HIV / AIDS Therapeutics – Discontinued Products
- HIV / AIDS Therapeutics - Dormant Products
- HIV / AIDS – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for HIV / AIDS, H2 2012
- Products under Development for HIV / AIDS – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Development by Companies, H2 2012 (Contd..1)
- Number of Products under Development by Companies, H2 2012 (Contd..2)
- Number of Products under Development by Companies, H2 2012 (Contd..3)
- Number of Products under Development by Companies, H2 2012 (Contd..4)
- Number of Products under Development by Companies, H2 2012 (Contd..5)
- Number of Products under Development by Companies, H2 2012 (Contd..6)
- Number of Products under Development by Companies, H2 2012 (Contd..7)
- Number of Products under Development by Companies, H2 2012 (Contd..8)
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2)
- Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3)
- Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4)
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Development by Companies, H2 2012 (Contd..1)
- Products under Development by Companies, H2 2012 (Contd..2)
- Products under Development by Companies, H2 2012 (Contd..3)
- Products under Development by Companies, H2 2012 (Contd..4)
- Products under Development by Companies, H2 2012 (Contd..5)
- Products under Development by Companies, H2 2012 (Contd..6)
- Products under Development by Companies, H2 2012 (Contd..7)
- Products under Development by Companies, H2 2012 (Contd..8)
- Products under Development by Companies, H2 2012 (Contd..9)
- Products under Development by Companies, H2 2012 (Contd..10)
- Products under Development by Companies, H2 2012 (Contd..11)
- Products under Development by Companies, H2 2012 (Contd..12)
- Products under Investigation by Universities/Institutes, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..1)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..2)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..3)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..4)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..5)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..6)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..7)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..8)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..9)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..10)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..11)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..12)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..13)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..14)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..15)
- Products under Investigation by Universities/Institutes, H2 2012 (Contd..16)
- Bristol-Myers Squibb Company, H2 2012
- Johnson & Johnson, H2 2012
- Abbott Laboratories, H2 2012
- Vical Incorporated, H2 2012
- Shionogi & Co., Ltd., H2 2012
- GlaxoSmithKline plc, H2 2012
- Nektar Therapeutics, H2 2012
- Inovio Biomedical Corporation, H2 2012
- Gilead Sciences, Inc., H2 2012
- VIRxSYS Corporation, H2 2012
- Merck & Co., Inc., H2 2012
- United Biomedical, Inc., H2 2012
- Lentigen Corporation, H2 2012
- Myriad Genetics, Inc., H2 2012
- Sangamo BioSciences, Inc., H2 2012
- Cytokine PharmaSciences, Inc., H2 2012
- Generex Biotechnology Corporation, H2 2012
- Ceragenix Pharmaceuticals, Inc., H2 2012
- Nanotherapeutics, Inc., H2 2012
- Ambrilia Biopharma Inc., H2 2012
- Panacos Pharmaceuticals, Inc., H2 2012
- Biotron Limited, H2 2012
- Aphios Corporation, H2 2012
- Achillion Pharmaceuticals, Inc., H2 2012
- Esteve Group, H2 2012
- Japan Tobacco Inc., H2 2012
- Pfizer Inc., H2 2012
- SuperGen, Inc., H2 2012
- Hadasit Medical Research Services & Development Ltd, H2 2012
- Avexa Limited, H2 2012
- Koronis Pharmaceuticals, Inc., H2 2012
- Alfacell Corporation, H2 2012
- Geron Corporation, H2 2012
- GeoVax Labs, Inc., H2 2012
- Hemispherx Biopharma, Inc., H2 2012
- Celldex Therapeutics, Inc., H2 2012
- iCo Therapeutics Inc., H2 2012
- Enzo Biochem, Inc., H2 2012
- Ardea Biosciences, Inc., H2 2012
- Medivir AB, H2 2012
- Bio-Bridge Science, Inc., H2 2012
- Mymetics Corporation, H2 2012
- NanoViricides, Inc., H2 2012
- Nutra Pharma Corporation, H2 2012
- ConjuChem Biotechnologies Inc., H2 2012
- Critical Outcome Technologies Inc., H2 2012
- CytoGenix, Inc., H2 2012
- ADVENTRX Pharmaceuticals, H2 2012
- Starpharma Holdings Limited, H2 2012
- Immuron Limited, H2 2012
- Samaritan Pharmaceuticals, Inc., H2 2012
- Takara Bio Inc., H2 2012
- BioAlliance Pharma SA, H2 2012
- Transgene Biotek Ltd, H2 2012
- Paloma Pharmaceuticals, Inc., H2 2012
- Antigen Express, Inc., H2 2012
- Functional Genetics, Inc., H2 2012
- BioClonetics Incorporated, H2 2012
- Nutri Pharma ASA, H2 2012
- Pharmaplaz Ltd., H2 2012
- BioMAS Ltd., H2 2012
- Vironova AB, H2 2012
- ViroStatics, srl, H2 2012
- Argos Therapeutics, Inc., H2 2012
- Cytheris SA, H2 2012
- Altor BioScience Corporation, H2 2012
- PX’Therapeutics SA, H2 2012
- Osel Inc., H2 2012
- Heat Biologics, Inc., H2 2012
- AiCuris GmbH & Co. KG, H2 2012
- AlphaVax, Inc., H2 2012
- Indus Biotech Private Limited, H2 2012
- Locus Pharmaceuticals, Inc., H2 2012
- Presidio Pharmaceuticals, Inc., H2 2012
- Theraclone Sciences, Inc., H2 2012
- Frontier Biotechnologies, Inc., H2 2012
- Kainos Medicine, Inc., H2 2012
- Viral Genetics, Inc., H2 2012
- Concert Pharmaceuticals, Inc., H2 2012
- Myriad Pharmaceuticals, Inc., H2 2012
- CytoDyn, Inc., H2 2012
- GeneCure LLC, H2 2012
- Omeros Corporation, H2 2012
- Oncolys BioPharma Inc., H2 2012
- Globeimmune, Inc., H2 2012
- Etubics Corporation, H2 2012
- Immunocore Limited., H2 2012
- Canopus BioPharma Incorporated, H2 2012
- Discovery Genomics, Inc., H2 2012
- PepTcell Limited, H2 2012
- Arisyn Therapeutics Inc., H2 2012
- TVAX Biomedical, LLC, H2 2012
- Tobira Therapeutics, Inc., H2 2012
- Genetic Immunity, LLC, H2 2012
- TNI Pharmaceuticals, Inc., H2 2012
- GenPhar, Inc., H2 2012
- Medisyn Technologies, Inc., H2 2012
- Napo Pharmaceuticals, Inc., H2 2012
- Pharis Biotec GmbH, H2 2012
- Immunomic Therapeutics, Inc., H2 2012
- GeoVax, Inc., H2 2012
- Heptares Therapeutics Ltd., H2 2012
- VIRIOM Ltd., H2 2012
- CONRAD, H2 2012
- ViiV Healthcare, H2 2012
- RFS Pharma, LLC, H2 2012
- Helix Therapeutics LLC, H2 2012
- Vichem Chemie Research Ltd., H2 2012
- ImQuest Life Sciences, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- HIV / AIDS Therapeutics – Drug Profile Updates
- HIV / AIDS Therapeutics – Discontinued Products
- HIV / AIDS Therapeutics – Discontinued Products (Contd..1)
- HIV / AIDS Therapeutics – Discontinued Products (Contd..2)
- HIV / AIDS Therapeutics – Discontinued Products (Contd..3)
- HIV / AIDS Therapeutics – Discontinued Products (Contd..4)
- HIV / AIDS Therapeutics – Discontinued Products (Contd..5)
- HIV / AIDS Therapeutics – Discontinued Products (Contd..6)
- HIV / AIDS Therapeutics – Discontinued Products (Contd..7)
- HIV / AIDS Therapeutics – Discontinued Products (Contd..8)
- HIV / AIDS Therapeutics – Dormant Products
- HIV / AIDS Therapeutics – Dormant Products (Contd..1)
- HIV / AIDS Therapeutics – Dormant Products (Contd..2)
- HIV / AIDS Therapeutics – Dormant Products (Contd..3)
- HIV / AIDS Therapeutics – Dormant Products (Contd..4)
- HIV / AIDS Therapeutics – Dormant Products (Contd..5)
- HIV / AIDS Therapeutics – Dormant Products (Contd..6)
- HIV / AIDS Therapeutics – Dormant Products (Contd..7)
- HIV / AIDS Therapeutics – Dormant Products (Contd..8)
- HIV / AIDS Therapeutics – Dormant Products (Contd..9)
- HIV / AIDS Therapeutics – Dormant Products (Contd..10)
- HIV / AIDS Therapeutics – Dormant Products (Contd..11)
- HIV / AIDS Therapeutics – Dormant Products (Contd..12)
- HIV / AIDS Therapeutics – Dormant Products (Contd..13)
- HIV / AIDS Therapeutics – Dormant Products (Contd..14)
- HIV / AIDS Therapeutics – Dormant Products (Contd..15)
- HIV / AIDS Therapeutics – Dormant Products (Contd..16)
- HIV / AIDS Therapeutics – Dormant Products (Contd..17)
- HIV / AIDS Therapeutics – Dormant Products (Contd..18)
- HIV / AIDS Therapeutics – Dormant Products (Contd..19)
- HIV / AIDS Therapeutics – Dormant Products (Contd..20)
- HIV / AIDS Therapeutics – Dormant Products (Contd..21)
- HIV / AIDS Therapeutics – Dormant Products (Contd..22)
- HIV / AIDS Therapeutics – Dormant Products (Contd..23)
- HIV / AIDS Therapeutics – Dormant Products (Contd..24)
- HIV / AIDS Therapeutics – Dormant Products (Contd..25)
- HIV / AIDS Therapeutics – Dormant Products (Contd..26)
- HIV / AIDS Therapeutics – Dormant Products (Contd..27)
- HIV / AIDS Therapeutics – Dormant Products (Contd..28)
- HIV / AIDS Therapeutics – Dormant Products (Contd..29)
- HIV / AIDS Therapeutics – Dormant Products (Contd..30)
- HIV / AIDS Therapeutics – Dormant Products (Contd..31)
- HIV / AIDS Therapeutics – Dormant Products (Contd..32)
- HIV / AIDS Therapeutics – Dormant Products (Contd..33)
- HIV / AIDS Therapeutics – Dormant Products (Contd..34)
- HIV / AIDS Therapeutics – Dormant Products (Contd..35)
- HIV / AIDS Therapeutics – Dormant Products (Contd..36)
- HIV / AIDS Therapeutics – Dormant Products (Contd..37)
- HIV / AIDS Therapeutics – Dormant Products (Contd..38)
- HIV / AIDS Therapeutics – Dormant Products (Contd..39)
- HIV / AIDS Therapeutics – Dormant Products (Contd..40)
- HIV / AIDS Therapeutics – Dormant Products (Contd..41)
- HIV / AIDS Therapeutics – Dormant Products (Contd..42)
- HIV / AIDS Therapeutics – Dormant Products (Contd..43)
- HIV / AIDS Therapeutics – Dormant Products (Contd..44)
- HIV / AIDS Therapeutics – Dormant Products (Contd..45)
- HIV / AIDS Therapeutics – Dormant Products (Contd..46)
- HIV / AIDS Therapeutics – Dormant Products (Contd..47)
- HIV / AIDS Therapeutics – Dormant Products (Contd..48)
- HIV / AIDS Therapeutics – Dormant Products (Contd..49)
- HIV / AIDS Therapeutics – Dormant Products (Contd..50)
- HIV / AIDS Therapeutics – Dormant Products (Contd..51)
- HIV / AIDS Therapeutics – Dormant Products (Contd..52)
- HIV / AIDS Therapeutics – Dormant Products (Contd..53)
- HIV / AIDS Therapeutics – Dormant Products (Contd..54)
- HIV / AIDS Therapeutics – Dormant Products (Contd..55)
- List of Figures
- Number of Products under Development for HIV / AIDS, H2 2012
- Products under Development for HIV / AIDS – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractHIV / AIDS – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'HIV / AIDS - Pipeline Review, H2 2012', provides an overview of the HIV / AIDS therapeutic pipeline. This report provides information on the therapeutic development for HIV / AIDS, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV / AIDS. 'HIV / AIDS - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for HIV / AIDS.
- A review of the HIV / AIDS products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the HIV / AIDS pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for HIV / AIDS.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding HIV / AIDS pipeline depth and focus of HIV / AIDS therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
